DBV Technologies S.A. (DBVT) Dividend History

Company News

• DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

  DBV Technologies, a biopharmaceutical company, announced the filing of its 2024 Annual Report and Universal Registration Document, which include audited financial statements and other regulatory filings.

  GlobeNewswire Inc.
• DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying

  The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Dalrada Financial The Trade: Dalrada Financial Corporation (OTC: DFCO) Chief Executive Officer Brian Bonar acquired a total of 52,600 shares an average price of $0.22. To acquire these ...

  Benzinga

  Featured Companies: REFR
• Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

  DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  Zacks Investment Research
• Why Shares of DBV Technologies Jumped Thursday

  "The New England Journal of Medicine" reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.

  The Motley Fool